Patients achieved an estimated weight loss of 9.7% on 1.25 mg after 20 weeks, 16.2% on 5 mg after 28 weeks and 22% on 20 mg after 36 weeks. The figures come from an analysis that assessed the ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Semaglutide, the drug sold as Ozempic to treat type 2 diabetes and Wegovy for weight loss, reduced alcohol cravings and ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

The first clinical trial of its kind found the weekly semaglutide jab cuts the amount people drink in one day by 40 per cent ...

In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two issues in the anti-obesity space.

It revealed that sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year, from 9.6 billion kroner (£1.1 ...